More than 67% of patients who received AR101 were able to ingest a dose of 600 mg or more of peanut protein at the exit food challenge, without dose-limiting symptoms
Treatment reinitiation after a short interruption was well tolerated in patients taking standardized quality house mite sublingual immunotherapy tablets.
Patients who received olopatadine/mometasone either once or twice daily experienced significant improvements in their instantaneous Total Nasal Symptom Scores compared with placebo.
Significantly greater reductions in the mean esophageal eosinophil counts occurred in patients who received the humanized anti-interleukin 13 antibody, RPC4046.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.